Contract development and manufacturing organization (CDMO) Recipharm has appointed Bernard Pluta to lead its new global development organization.
The newly established position forms part of the ongoing transformation of Recipharm’s Development Services, in which a total of 400 employees across six countries are united to deliver a comprehensive development offering.
The scientific, chemical, and pharmaceutical expertise will cover end to end development services, ranging from development of the active compound to providing dossiers for marketing authorization applications in all major geographies. The combined capabilities and capacities will provide the CDMO’s customers with an efficient pathway to commercialization.
Bernard Pluta. (Credit: Reciharm AB)
Bernard Pluta is currently the General Manager of Recipharm’s manufacturing and development operations in Pessac, France and recently led a group wide project focusing on optimizing and coordinating Recipharm’s extensive development capacities in Sweden, Italy, France, U.S., India, and Israel.
“I am delighted to announce the appointment of Bernard Pluta as President, Development Services,” CEO Thomas Eldered said. “Bernard has managed our operations in Pessac with great success. His industry expertise and solid business competence will play a key role in transforming our development services and ensuring a seamless end to end offering. By providing a wide range of development services we are well positioned to manage challenging projects and complexity on behalf of our customers.”
Bernard Pluta has experience in the pharma and CDMO industry having held executive positions with Theramex, Merck Serono, and Teva. He also ran his own CMO consultancy business before joining Recipharm in 2015 and he holds a dual degree as Industrial Engineer and MBA.
In his role as President, Development Services, Pluta will report to Eldered and be a part of the group management team. He will continue as General Manager of Recipharm in Pessac until a successor has been appointed.
Recipharm’s new development organization will be implemented during the first half of 2018. Development services will continue to be reported as part of Recipharm’s Development & Technology segment.
(Source: Recipharm AB)
